Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-04: ALX148 with pembrolizumab and chemotherapy in advanced head and neck squamous cell carcinoma
NL-OMON54403Phase 2Recruiting
- Sponsor
- ALX Oncology
- Start
- Jun 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of evorpacept in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by ALX Oncology. Primary endpoints: 12-month overall survival rate and Objective response rate. Started Jun 2023; status: recruiting.
02
Drugs
evorpacept
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON54403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54403.